A phase II trial of eltrombopag for patients w... - CLL Support

CLL Support

23,088 members39,648 posts

A phase II trial of eltrombopag for patients with CLL and thrombocytopenia

Jm954 profile image
Jm954Administrator
1 Reply

Nov 2018

Eltrombopag is an oral thrombopoietin (TPO)‐receptor agonist that induces proliferation and differentiation of megakaryocytes. Eltrombopag is approved for the treatment of chronic immune thrombocytopenia purpura (ITP) after insufficient response to standard therapy.

Approximately 5% of patients with previously‐untreated chronic lymphocytic leukaemia (CLL) and 25–30% of patients with previously‐treated CLL have thrombocytopenia (Tsang & Parikh, 2017). As thrombocytopenia is commonly seen in active CLL, the diagnosis of CLL‐associated ITP can be difficult.

ITP is a result of auto‐antibodies leading to platelet destruction. Conventional treatment is focused on targeting the immune destruction of platelets through the use of corticosteroids, immunoglobulins and immunosuppressive agents. Splenectomy is another effective treatment but is infrequently used.

Eltrombopag, an oral TPO‐receptor agonist, activates intracellular signal transduction, leading to an increase in differentiation and proliferation of bone marrow progenitor cells resulting in an increased platelet count.

In this phase II study, eltrombopag was evaluated as a treatment for thrombocytopenia in patients with CLL (NCT01168921).

This study highlights the effectiveness of eltrombopag in patients with CLL‐associated ITP who are refractory to standard ITP treatments. The response rate of 82% is encouraging and is similar to those seen in patients with chronic ITP.

Notably, the response rate to eltrombopag was lower in patients with CLL where thrombocytopenia was deemed not immune‐mediated.

As treatment options for CLL have evolved from cytotoxic chemotherapy to oral targeted therapies (Jain & O'Brien, 2016), further studies are warranted to assess the benefit of eltrombopag in the setting of thrombocytopenia associated with oral targeted therapies.

More here: onlinelibrary.wiley.com/doi...

Jackie

Written by
Jm954 profile image
Jm954
Administrator
To view profiles and participate in discussions please or .
Read more about...
1 Reply
Wroxham profile image
Wroxham

Hi Jackie

Excellent description of something that is new to me. I have read through, saved the post and also hopefully stored away in my brain.

Well worth reading everyone.

Sue

Not what you're looking for?

You may also like...

Autoimmune hemolytic anemia (AIHA), Immune thrombocytopenia (ITP) and other autoimmune complications and extranodal involvement in CLL

"Autoimmune conditions are common in CLL and are often managed in a distinct manner from primary...

Towards personalised management of CLL? Ibrutinib study reveals new way to gauge patients’ response to treatment

Excerpts from...

Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL

"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and...

Clinical trial results & reviews of new treatments for CLL written in easy to understand terms

Anyone interested in reading a weekly update of the latest breaking news for CLL may want to sign...

A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lym

Background: Current therapies for CLL/SLL have frequent toxicities, are non-curative, and several...